Europe Insulin Pen Market - By Type, By Indication, By Distribution Channel - Regional Forecast, 2025 - 2034

Europe Insulin Pen Market Size

The Europe insulin pen market was valued at USD 2.7 billion in 2024 and is projected to grow from USD 3 billion in 2025 to USD 7.4 billion by 2034, expanding at a CAGR of 10.5%, according to the latest report published by Global Market Insights Inc. This steady growth is stimulated by various factors such as rising diabetes prevalence across Europe, technological advancements, government support and reimbursement policies, and increasing geriatric population base. Major companies in the industry include Novo Nordisk, Sanofi, Eli Lilly and Company, and Ypsomed.

The market increased from USD 2 billion in 2021 to USD 2.5 billion in 2023. The increasing prevalence of diabetes in Europe is a major driver of the insulin pen market. For instance, according to the International Diabetes Federation (IDF), 9.8% of Europe’s population, or 66 million individuals, currently live with diabetes. This figure is projected to rise by 10% by 2050. Additionally, the region has the highest number of type 1 diabetes cases globally, totaling 2.7 million, with 15% of these individuals under the age of 20. This consistent rise in diabetes cases highlights the urgent need for accessible and efficient insulin delivery solutions, positioning insulin pens as a critical component of diabetes care in Europe.
 

Furthermore, technological advancements are significantly driving the growth of the insulin pen market in Europe, as manufacturers respond to the increasing demand for efficient and user-friendly diabetes management tools. Modern pens now feature bluetooth connectivity, memory functions, dose tracking, and integration with mobile health apps. For example, devices such as NovoPen 6 and InPen can automatically log insulin doses and sync with glucose monitoring systems. These innovations not only improve dosing accuracy but also enable real-time data sharing with healthcare providers, supporting personalized treatment and better patient outcomes.
 

An insulin pen is a medical device designed to deliver insulin to individuals with diabetes in a convenient, accurate, and user-friendly manner. It typically consists of an insulin cartridge, a dial for selecting the required dose, and a disposable needle for injection. Insulin pens are available in two main types disposable pens, which come pre-filled and are discarded after use, and reusable pens, which use replaceable insulin cartridges.
 

Europe Insulin Pen Market Trends

• Europe's aging population is a significant factor driving the growth of the insulin pen market. The region is witnessing a steady increase in older adults due to higher life expectancy and declining birth rates. As of January 2024, the European Union’s population stands at 449.3 million, with 21.6% aged 65 years and above.
   
• This demographic shift is closely linked to a higher prevalence of chronic conditions such as diabetes, which disproportionately affects seniors. Age-related changes, including reduced insulin sensitivity and impaired glucose metabolism, significantly increase the risk of type 2 diabetes among this group. Thus, the demand for convenient and reliable insulin delivery solutions is rising.
   
• Insulin pens, known for their ease of use, accurate dosing, and minimal training requirements, are particularly suitable for elderly patients who may find traditional syringes challenging.
   
• Additionally, modern pens equipped with memory functions and dose tracking enable caregivers and healthcare professionals to monitor adherence, ensuring better disease management. As Europe’s population continues to age, the need for accessible, patient-friendly diabetes care solutions positions insulin pens as a critical component of future treatment strategies, driving sustained market growth.
   

Europe Insulin Pen Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on type, the market is segmented into reusable and disposable insulin pens. The reusable insulin pens segment accounted for 37.4% of the market in 2024 due to their cost-effectiveness, environmental sustainability, and long-term usability. The segment is expected to exceed USD 2.8 billion by 2034, growing with the fastest CAGR of 10.6% during the forecast period. On the other hand, disposable insulin pen segment is expected to grow at CAGR of 10.5%.
 

• Disposable insulin pens dominate the European market due to their ease of use, lower cost, and widespread availability. They are particularly popular among newly diagnosed patients.
   
• Their pre-filled, ready-to-use format makes them ideal for emergency situations and travel, eliminating the need for cartridge replacement. For example, Eli Lilly and Company offers the KwikPen series, prefilled with Humalog, featuring a compact design, audible dose clicks, and smooth dose delivery for enhanced convenience.
   
• Additionally, disposable pens also reduce the risk of dosing errors and require no maintenance or cleaning, benefiting both patients and healthcare providers. These advantages are especially valuable for elderly individuals or patients with limited dexterity, as well as caregivers managing multiple patients in clinical settings.
   
• Thus, disposable insulin pens continue to drive significant growth in the European insulin pen market.
   

Based on the indication, the Europe insulin pen market is segmented into type 1 diabetes, type 2 diabetes, and gestational diabetes. The type 1 diabetes segment dominated the market in 2024 with a revenue of USD 1.6 billion.
 

• The type 1 diabetes segment holds a dominant position in the European insulin pen market, primarily due to the lifelong need for insulin therapy among affected individuals. Patients with type 1 diabetes require multiple daily injections from an early age, making insulin pens the preferred choice for their ease of use, portability, and dosing precision.
   
• For instance, according to the International Diabetes Federation (IDF), the Europe Region has the highest number of people with type 1 diabetes globally, approximately 2.7 million, with 15% under the age of 20. These figures highlight the significant healthcare investment and growing demand for effective insulin delivery solutions.
   
• Further, insulin pens are particularly beneficial for younger patients, offering a discreet design, reduced injection pain, and user-friendly features that support better adherence and glycemic control. These advantages are crucial for long-term health outcomes, reinforcing the strong market position of insulin pens in managing type 1 diabetes across Europe.

Learn more about the key segments shaping this market

Download Free PDF

Based on distribution channels, the Europe insulin pen market is classified into hospital pharmacies, retail pharmacies, and e-commerce. The hospitals pharmacies segment dominated the market in 2024 and is expected to reach USD 3.5 billion by 2034.
 

• Hospital pharmacies play an important role in the distribution of insulin pens across Europe due to their integration within national healthcare systems. They act as the primary access point for prescription-only medicines, including insulin pens, particularly for newly diagnosed patients and those under specialist care.
   
• By ensuring a consistent supply, regulated pricing, and professional oversight, hospital pharmacies significantly contribute to market growth. Their structured procurement processes and direct partnerships with manufacturers help maintain availability and minimize shortages.
   
• Additionally, hospital pharmacies provide clinical support, patient education, and monitoring, which improve adherence and treatment outcomes. Their involvement in initiating insulin therapy, especially for type 1 diabetes and complex cases, ensures proper device selection and training, reinforcing their pivotal role in the European insulin pen market.

Looking for region specific data?

Download Free PDF

Germany Insulin Pen Market
 

The market was valued at USD 288.5 million and USD 312.8 million in 2021 and 2022, respectively. In 2024, the market size reached USD 379 million from USD 341.6 million in 2023.
 

• The increasing number of diabetes cases in Germany is one of the primary reasons behind the rising demand for insulin delivery systems, such as insulin pens.
   
• For instance, according to the International Diabetes Federation (IDF), in Germany (2021), the total adult population was approximately 62 million, with a diabetes prevalence of 10%, resulting in around 6.2 million adults living with diabetes. This substantial patient base highlights the growing demand for effective insulin delivery solutions, such as insulin pens, especially in countries with a high diabetes burden.
   
• Additionally, Germany’s healthcare system emphasizes early diagnosis and long-term management of chronic illnesses, which supports the widespread adoption of insulin pens. Their ease of use, portability, and reduced risk of dosing errors make them especially valuable in both clinical and home settings, helping improve treatment adherence and outcomes.
   
• Therefore, the steady rise in diabetes cases is stimulating the insulin pen market to grow.
   

France insulin pen market is projected to experience steady growth between 2025 and 2034.
 

• France is experiencing a steady increase in its aging population, which is influencing the demand for advanced insulin delivery solutions.
   
• For instance, projections indicate that by 2050, people aged sixty-five and older will make up 27% of France's population compared to 21% today. Additionally, the proportion of individuals aged eighty and above is expected to nearly double, rising from 6% to over 11%. This increase in the elderly population will lead to more hospital visits and a higher demand for safe insulin delivery.
   
• Therefore, the increasing aging population and the growing diabetes burden in France are driving the growth of the insulin pen market across the country.
   

UK insulin pen market was market accounted for USD 309.6 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• The UK is witnessing a steady rise in diabetes cases, particularly among its aging population. As diabetes becomes more prevalent, the demand for effective and user-friendly treatment options, such as insulin pens, is growing. These devices offer greater convenience, accuracy, and ease of use, making them especially suitable for elderly patients and those managing long-term conditions.
   
• For instance, in 2021, the UK had a total adult population of approximately 47.9 million, with 5.6% of adults diagnosed with diabetes, amounting to over 2.68 million cases. The International Diabetes Federation (IDF) projects that the number of people with diabetes in the EUR region will rise from 59 million to 68 million by 2045, indicating a significant future burden on healthcare systems.
   
• Therefore, the UK's increasing aging population is stimulating the growth of the insulin pen market across the country.
   

The Italy insulin pen market was projected to be valued at USD 186 million in 2025 and is expected to reach USD 460.8 million by 2034.
 

• The growing demand for chronic disease management, particularly diabetes, is driving the expansion of the insulin pen market in Italy. As of 2023, approximately 3.7 million people in Italy were living with diabetes, with the majority aged 75 years or older. The age-standardized prevalence among adults aged 20–79 was 7.7%, and this figure is projected to rise to 9.2% by 2050. Italy currently ranks fourth in the IDF Europe Region for the number of adults with diabetes, underscoring the scale of the condition nationally.
   
• As people age, they become more susceptible to chronic conditions such as diabetes, which require consistent and effective management. This trend is fueling demand for user-friendly and precise treatment options, such as insulin pens, which offer a convenient and reliable way to administer insulin, particularly for elderly patients.
   

Spain insulin pen market is poised to witness lucrative growth between 2025 - 2034 with CAGR of 10.4%.
 

• Spain has one of the fastest-aging populations, coupled with a rising burden of chronic diseases. As of 2023, approximately 54.3% of Spain’s population aged 15 and older, equating to over 22 million people, were living with at least one chronic condition, such as diabetes, which often requires insulin therapy. This demographic trend is driving significant demand for convenient and effective insulin delivery solutions.
   
• Further, Spain’s well-established healthcare system and structured distribution channels ensure the accessibility and affordability of insulin pens. Hospitals and clinics currently contribute the largest share of the market, with home care adoption rising rapidly.
   

Europe Insulin Pen Market Share

• The European insulin pen market is highly consolidated, with the top five players Novo Nordisk, Eli Lilly, Sanofi, Ypsomed, and Becton Dickinson & Company collectively accounting for around 55% of the total market share. Their dominance is driven by extensive product portfolios, robust distribution networks, strong regulatory compliance, and continuous innovation.
   
• Sanofi stands out with its comprehensive range of advanced insulin delivery solutions and a strong emphasis on patient-centric innovation and integrated diabetes care. The company offers high-quality insulin pens designed for precision, ease of use, and reliability, catering to both type 1 and type 2 diabetes patients. Its competitive advantage lies in technological advancements, including smart insulin pens, which is estimated to reach USD 1.9 billion by 2032, equipped with dose tracking and connectivity features that integrate seamlessly with digital health platforms.
   
• Emerging players and new entrants are gaining traction by focusing on innovation, strategic acquisitions, and niche applications, helping diversify the market and improve access to effective treatment solutions.
   
• To strengthen their positions, both established and emerging companies frequently engage in partnerships, licensing deals, and acquisitions, enabling them to expand product capabilities, integrate new technologies, and enhance competitiveness in the rapidly growing insulin pen market.
   

Europe Insulin Pen Market Companies

Few of the prominent players operating in the Europe insulin pen industry include:
 

• Becton, Dickinson and Company
• Biocon Biologics
• Eli Lilly and Company
• Gan & Lee Pharmaceuticals
• Haselmeier
• Medtronic
• Medmix
• Novo Nordisk
• Owen Mumford
• Sanofi
• Ypsomed
• Wockhardt
   

• Owen Mumford

Owen Mumford is recognized for its innovative injection devices, including auto-injectors and pen injectors designed for ease of use and patient comfort. The company’s strengths lie in ergonomic designs, reusable pen platforms, and sustainability initiatives.  
 

• Becton, Dickinson and Company

Becton, Dickinson and Company strengthens its position in the insulin pen market through a focus on smart diabetes technologies, offering connected solutions that improve insulin delivery precision and enable patient monitoring. By integrating digital tools with its injection systems, the company supports personalized, data-driven diabetes care, enhancing treatment adherence and overall patient outcomes.  
 

• Ypsomed

Ypsomed known for its innovation in self-injection systems and pen technology. The company offers a wide range of customizable pen injectors and smart insulin pens that support digital health integration. With a strong focus on user-centric design, sustainability, and partnerships with major insulin manufacturers, Ypsomed continues to expand its global footprint. 
 

Europe Insulin Pen Industry News

• In February 2023, Glooko, a global digital health company specializing in diabetes data management, announced a strategic partnership with Sanofi to integrate SoloSmart a connected cap device for SoloStar and DoubleStar insulin pens into the Glooko platform. This collaboration aimed to advance connected care and improve insulin management for people living with diabetes by enabling better data-driven treatment decisions.
   

The Europe insulin pen market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million and from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Reusable insulin pens
• Disposable insulin pens 

Market, By Indication

• Type 1 diabetes
• Type 2 diabetes
• Gestational diabetes

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• E-commerce